Beta Bionics Publishes 100% of iLet Patient Outcomes with No Exclusions
BBNX•Beta Bionics now publishes near real-time outcomes for 100% of iLet Bionic Pancreas patients meeting two criteria—provider-reported baseline HbA1c and at least two weeks of cloud data—with no exclusions on its public dashboard. The updated dashboard at betabionics.com/hcp/real-world-data offers clinicians and payers unfiltered metrics to evaluate automated insulin delivery performance.
1. Dashboard Launch and Criteria
Beta Bionics launched a new dashboard on its website that publicly publishes near real-time outcomes for every iLet Bionic Pancreas user who has a provider-reported baseline HbA1c and at least two weeks of cloud data, without applying any exclusions. The platform displays individual patient metrics, enabling a full view of system performance across 100% of qualified users.
2. Transparency Principles and Guide
The dashboard is built upon six guiding principles that outline clear inclusion criteria, baseline reporting, device settings and time frame, accompanied by a companion guide for evaluating real-world AID data. This framework ensures consistent interpretation of outcomes and fosters unbiased comparison among automated insulin delivery systems.
3. Stakeholder Implications
Clinicians, researchers, payers and patients can access unfiltered metrics to assess glycemic control, time-in-range and other key performance indicators, supporting informed decision-making on AID adoption and reimbursement. Continuous public data may accelerate clinical discussions and strengthen confidence in the iLet’s real-world efficacy.
4. Industry Standard and Upcoming Sessions
By openly sharing unfiltered real-world data, Beta Bionics aims to set a new industry benchmark and encourages other AID companies to follow suit. The dashboard launch precedes the American Diabetes Association’s 86th Scientific Sessions, where the company plans to showcase its transparency initiative to healthcare providers.
